To Radiate or Not to Radiate? Updates to Management of Retroperitoneal Sarcoma
Retroperitoneal sarcomas (RPS), a rare subset of soft tissue sarcomas, account for 10-15% of these cases and are distinguished by their substantial size, infiltrative nature, and proximity to vital anatomical structures.
Category
  • Sarcoma
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Radiation as an Immune Catalyst: Techniques, Biology and Biomaterials for Enhancing Tumor Control
Increasing evidence has demonstrated the importance of immunomodulation on tumor control. Radiotherapy, specifically, can produce a multitude of local and systemic immunomodulatory effects, including reprogramming the tumor microenvironment and exposing tumor antigens via in situ vaccination.
Category
  • Immunotherapy
  • Radiobiology
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
ASTRO/KCA Joint Activity: Stereotactic Radiotherapy and Renal Cell Cancer, Overcoming Radioresistance and the Resistance to Radiate
This activity brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC).
Category
  • SBRT
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Designing, Implementing and Interpreting Patient Reported Outcomes in Clinical Investigation
Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.
Category
  • Professional Development
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00

Pages